Buttar Sana N, Yan Tristan D, Taggart David P, Tian David H
The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia.
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
Heart. 2017 Sep;103(18):1419-1426. doi: 10.1136/heartjnl-2016-310864. Epub 2017 Jun 23.
A substantial body of evidence demonstrates that myocardial revascularisation using bilateral internal mammary arteries (BIMA) improves long-term survival compared with single/left internal mammary artery (LIMA) grafting. To date, limited analyses have been made regarding other short-term and long-term outcomes in BIMA strategy.
The primary aim of the present review is to update the difference in long-term survival between BIMA and LIMA grafting and to thoroughly investigate other secondary short-term and long-term clinical outcomes between these two grafting procedures.
Electronic searches were performed using three databases from their inception to November 2015. Relevant studies comparing long-term survival between BIMA and LIMA grafting were identified. Data were extracted by two independent reviewers and analysed according to predefined clinical outcomes.
Twenty-nine observational studies were identified, with a total of 89 399 patients. Overall, BIMA cohort had significantly improved long-term survival compared with LIMA cohort (HR 0.78; p<0.00001). BIMA cohort also had significantly reduced hospital mortality rates (1.2% vs 2.1%, p=0.04), cerebrovascular accidents (1.3% vs 2.9%, p=0.0003) and need for revascularisation (4.8% vs 10%, p=0.005), although the incidence of deep sternal wound infection (DSWI) was increased (1.8% vs 1.4%, p=0.0008) in this grafting strategy. Long-term cardiac-free, myocardial infarction-free and angina-free survivals were also superior for the BIMA cohort.
BIMA grafting is associated with enhanced overall long-term outcomes compared with LIMA grafting. While the BIMA cohort demonstrates an increased incidence of DSWI, the survival benefits and other morbidity advantages outweigh this short-term risk.
大量证据表明,与使用单支/左乳内动脉(LIMA)移植相比,采用双侧乳内动脉(BIMA)进行心肌血运重建可改善长期生存率。迄今为止,关于BIMA策略的其他短期和长期结局的分析有限。
本综述的主要目的是更新BIMA和LIMA移植在长期生存方面的差异,并深入研究这两种移植方法之间其他次要的短期和长期临床结局。
使用三个数据库从建库至2015年11月进行电子检索。确定了比较BIMA和LIMA移植长期生存情况的相关研究。由两名独立的审阅者提取数据,并根据预先定义的临床结局进行分析。
共确定了29项观察性研究,涉及89399例患者。总体而言,与LIMA队列相比,BIMA队列的长期生存率显著提高(风险比0.78;p<0.00001)。BIMA队列的医院死亡率(1.2%对2.1%,p=0.04)、脑血管意外(1.3%对2.9%,p=0.0003)和血运重建需求(4.8%对10%,p=0.005)也显著降低,尽管在这种移植策略中,深部胸骨伤口感染(DSWI)的发生率有所增加(1.8%对1.4%,p=0.0008)。BIMA队列的长期无心脏事件、无心肌梗死和无心绞痛生存率也更高。
与LIMA移植相比,BIMA移植与总体长期结局改善相关。虽然BIMA队列显示DSWI的发生率增加,但生存获益和其他发病率优势超过了这种短期风险。